Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 4, 2013, Pages 1743-1755

  Deng, Pan ^a   Zhong, Dafang ^a   Yu, Kate ^b   Zhang, Yifan ^a   Wang, Ting ^c   Chen, Xiaoyan ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b WATERS CORPORATION   (United States)

^c LANZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARBIDOL; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 INHIBITOR; DIMETHYLANILINE MONOOXYGENASE; DRUG METABOLITE; GLUCURONIDE; KETOCONAZOLE; N DEMETHYLASE; N DEMETHYLSULFINYLARBIDOL; SULFATE; SULFINYLARBIDOL; SULFONYLARBIDOL; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG RETENTION; DRUG STABILITY; DRUG STRUCTURE; DRUG URINE LEVEL; GLUCURONIDATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SULFOXIDATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTIVIRAL AGENTS; FECES; HUMANS; INDOLES; MALE; YOUNG ADULT;

EID: 84875163069     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02282-12     Document Type: Article

References (22)

1. Boriskin YS, Leneva IA, Pecheur EI, Polyak SJ. 2008. Arbidol: a broadspectrum antiviral compound that blocks viral fusion. Curr. Med. Chem. 15:997-1005.
2. Teissier E, Zandomeneghi G, Loquet A, Lavillette D, Lavergne JP, Montserret R, Cosset FL, Bockmann A, Meier BH, Penin F, Pecheur EI. 2011. Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PLoS One 6:e15874. doi:10.1371/journal.pone.0015874.
3. Leneva IA, Russell RJ, Boriskin YS, Hay AJ. 2009. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 81:132-140.
4. Pecheur EI, Lavillette D, Alcaras F, Molle J, Boriskin YS, Roberts M, Cosset FL, Polyak SJ. 2007. Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol. Biochemistry (Moscow) 46:6050-6059.
5. Delogu I, Pastorino B, Baronti C, Nougairede A, Bonnet E, de Lamballerie X. 2011. In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. Antiviral Res. 90: 99-107.
6. Wang Y, Chen X, Li Q, Zhong D. 2008. Metabolite identification of arbidol in human urine by the study of CID fragmentation pathways using HPLC coupled with ion trap mass spectrometry. J. Mass Spectrom. 43: 1099-1109.
7. Liu X, Huang YW, Li J, Li XB, Bi KS, Chen XH. 2007. Determination of arbidol in human plasma by LC-ESI-MS. J. Pharm. Biomed. Anal. 43: 371-375.
8. Metz R, Muth P, Ferger M, Kukes VG, Vergin H. 1998. Sensitive high-performance liquid chromatographic determination of arbidol, a new antiviral compound, in human plasma. J. Chromatogr. A 810:63-69.
9. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. 2001. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab. Dispos. 29:1316-1324.
10. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095.
11. Rodrigues AD. 1999. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem. Pharmacol. 57:465-480.
12. Reichman M, Gill H. 2009. Automated drug screening for ADMET properties, p 150. In Nassar AF, Hollenberg PF, Scatina J (ed), Drug metabolism handbook: concepts and applications. John Wiley & Sons, Inc., Hoboken, NJ.
13. Wilkinson GR, Shand DG. 1975. Commentary: a physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. 18:377-390.
14. Yeung CK, Lang DH, Thummel KE, Rettie AE. 2000. Immunoquantitation of FMO1 in human liver, kidney, and intestine. Drug Metab. Dispos. 28:1107-1111.
15. Demin AV, Martianov VA, Shuster AM. 2010. Protein kinase C inhibitors exhibiting an anti-inflammatory, anti-allergic and anti-asthma effect. Russia patent WO/2010/064958.
16. Washio T, Arisawa H, Kohsaka K, Yasuda H. 2001. Identification of human drug-metabolizing enzymes involved in the metabolism of SNI-2011. Biol. Pharm. Bull. 24:1263-1266.
17. Usmani KA, Karoly ED, Hodgson E, Rose RL. 2004. In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavincontaining monooxygenase isoforms with particular reference to the CYP2C subfamily. Drug Metab. Dispos. 32:333-339.
18. Pike MG, Martin YN, Mays DC, Benson LM, Naylor S, Lipsky JJ. 1999. Roles of FMO and CYP450 in the metabolism in human liver microsomes of S-methyl-N,N-diethyldithiocarbamate, a disulfiram metabolite. Alcohol Clin. Exp. Res. 23:1173-1179.
19. Madan A, Parkinson A, Faiman MD. 1993. Role of flavin-dependent monooxygenases and cytochrome P450 enzymes in the sulfoxidation of S-methyl N,N-diethylthiolcarbamate. Biochem. Pharmacol. 46:2291-2297.
20. Leoni C, Buratti FM, Testai E. 2008. The participation of human hepatic P450 isoforms, flavin-containing monooxygenases and aldehyde oxidase in the biotransformation of the insecticide fenthion. Toxicol. Appl. Pharmacol. 233:343-352.
21. Virkel G, Lifschitz A, Sallovitz J, Pis A, Lanusse C. 2004. Comparative hepatic and extrahepatic enantioselective sulfoxidation of albendazole and fenbendazole in sheep and cattle. Drug Metab. Dispos. 32:536-544.
22. Haining RL, Hunter AP, Sadeque AJ, Philpot RM, Rettie AE. 1997. Baculovirus-mediated expression and purification of human FMO3: catalytic, immunochemical, and structural characterization. Drug Metab. Dispos. 25:790-797.